Another Step Towards Myeloma Market Dominance For Amgen's Kyprolis
This article was originally published in Scrip
Executive Summary
Amgen Inc.'s Kyprolis (carfilzomib) has been given the green light in Europe for the treatment of relapsed multiple myeloma, after being pushed through reviews under the European Medicines Agency's accelerated assessment program.